Page 633 - Read Online

Peyvandi et al. J Cancer Metastasis Treat 2019;5:44 I http://dx.doi.org/10.20517/2394-4722.2019.16 Page 21 of 24

153. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
154. Indraccolo S. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol 2013;734:37-
52.
155. Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle
2006;5:1751-5.
156. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, et al. Endothelial progenitor cells control the angiogenic switch in mouse lung
metastasis. Science 2008;319:195-8.
157. Laurent J, Touvrey C, Botta F, Kuonen F, Ruegg C. Emerging paradigms and questions on pro-angiogenic bone marrow-derived
myelomonocytic cells. Int J Dev Biol 2011;55:527-34.
158. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
159. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas
by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
160. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Cancer Cell 2009;16:67-78.
161. Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, et al. TGF-beta2 dictates disseminated tumour cell fate in target organs through
TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol 2013;15:1351-61.
162. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer
by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011;20:701-14.
163. Sosnoski DM, Norgard RJ, Grove CD, Foster SJ, Mastro AM. Dormancy and growth of metastatic breast cancer cells in a bone-like
microenvironment. Clin Exp Metastasis 2015;32:335-44.
164. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol
2002;3:991-8.
165. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science
2011;331:1565-70.
166. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol
2008;84:988-93.
167. Tuccitto A, Shahaj E, Vergani E, Ferro S, Huber V, et al. Immunosuppressive circuits in tumor microenvironment and their influence on
cancer treatment efficacy. Virchows Arch 2019;474:407-20.
168. Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, et al. Tumor microenvironment: Interactions and therapy. J Cell Physiol
2019;234:5700-21.
169. Groth C, Hu X, Weber R, Fleming V, Altevogt P, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs)
during tumour progression. Br J Cancer 2019;120:16-25.
170. Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer 2018;18:556.
171. Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, et al. Unresolved endoplasmic reticulum stress engenders immune-
resistant, latent pancreatic cancer metastases. Science 2018;360:eaao4908.
172. Matser YAH, Terpstra ML, Nadalin S, Nossent GD, de Boer J, et al. Transmission of breast cancer by a single multiorgan donor to 4
transplant recipients. Am J Transplant 2018;18:1810-4.
173. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011;11:702-
11.
174. Griffioen AW, Vyth-Dreese FA. Angiostasis as a way to improve immunotherapy. Thromb Haemost 2009;101:1025-31.
175. De Sanctis F, Ugel S, Facciponte J, Facciabene A. The dark side of tumor-associated endothelial cells. Semin Immunol 2018;35:35-47.
176. Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol
2018;15:310-24.
177. Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J 2018;24:193-204.
178. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. Production of vascular endothelial growth factor by human
tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
179. Bai WK, Zhang W, Hu B. Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer. Onco Targets
Ther 2018;11:1267-74.
180. Shi Y, Yu P, Zeng D, Qian F, Lei X, et al. Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability
of murine gastric cancer cells and elicits antitumor immunity. FEBS J 2014;281:3882-93.
181. Secondini C, Coquoz O, Spagnuolo L, Spinetti T, Peyvandi S, et al. Arginase inhibition suppresses lung metastasis in the 4T1
breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology
2017;6:e1316437.
182. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassara A, Wyser Rmili C, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor
immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med 2017;9:eaak9670.
183. Schmittnaegel M, De Palma M. Reprogramming tumor blood vessels for enhancing immunotherapy. Trends Cancer 2017;3:809-12.
184. Goddard ET, Bozic I, Riddell SR, Ghajar CM. Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol
2018;20:1240-9.
185. Ghajar CM. Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 2015;15:238-47.
186. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol
2010;7:22-36.
187. Schuetz F. Adjuvant systemic therapy of breast cancer. Breast Care (Basel) 2011;6:179-83.
188. Ejlertsen B. Adjuvant chemotherapy in early breast cancer. Dan Med J 2016;63.